Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis

Pharmacotherapy

Volumn 30, Issue 8, 2010, Pages 823-829

  Marrs, Joel C ^a   Saseen, Joseph J ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Chronic kidney disease; Dyslipidemia; Hemodialysis; Statins

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DYSLIPIDEMIA; HEART INFARCTION; HEMODIALYSIS; HUMAN; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; MORTALITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; REVIEW; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; HUMANS; HYPOLIPIDEMIC AGENTS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RISK ASSESSMENT;

EID: 77955462628     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.8.823     Document Type: Review

References (32)

1. Lloyd-Jones D, Adams R, Carthenon M, et al. Heart disease and stroke statistics - 2009 update: a report of the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2009;119:e21-181.
2. U.S. Renal Data System. USRDS 2009 annual data report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009. Available from http://www.usrds.org/atlas.htm. Accessed September 28, 2009.
3. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32:S112-19.
4. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 1996;49:1428-34.
5. Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000;58:353-62.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
7. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227-39.
8. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 suppl 1):S1-266.
9. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association council on kidney and cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003;108:2154-69.
10. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol 2008;51:2375-84.
11. Tsimihodimos V, Dounousi E, Siamopoulus KC. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol 2008;28:958-73.
12. Vaziri ND, Moradi H. Mechanism of dyslipidemia of chronic renal failure. Hemodial Int 2006;10:1-7.
13. Chan DT, Irish AB, Dogra GK, Watts GF. Dyslipidemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis 2008;196:823-34.
14. Fellstrom B, Holdaas H, Jardine AG, et al. Cardiovascular disease in patients with renal disease: the role of statins. Curr Med Res Opin 2009;25:271-85.
15. Kwan BC, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 2007;18:1246-61.
16. Liu J, Rosner MH. Lipid abnormalities associated with end stage renal disease. Semin Dialysis 2006;19:32-40. (Pubitemid 43479009)
17. Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Pathophysiology of dyslipidemia in the metabolic syndrome. Postgrad Med J 2005;81:358-66.
18. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemia in patients with kidney disease. Am J Kidney Dis 2003;41(suppl 3):S1-91.
19. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomized controlled trials. BMJ 2008;336:645-51.
20. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002;61:297-304.
21. Andreucci VE, Fissell RB, Bragg-Gresham JL, et al. Dialysis outcomes and practice patterns study (DOPPS) data on medication in hemodialysis patients. Am J Kidney Dis 2004;44:61-7.
22. Lins RL, Matthys KE, Billiouw JM, et al. Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. Clin Nephrol 2004:62:287-94.
23. Navaneethan SD, Nigwekar SU, Perkovic V, Johnson DW, Craig JC, Strippoli GFM. HMG-CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev 2009;(3):CD004289.
24. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407. (Erratum in N Engl J Med 2010;362:1450.)
25. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48. (Erratum in N Engl J Med 2005;353: 1640.)
26. Baigent C, Landry M. Study of heart and renal protection (SHARP). Kidney Int 2003;63:S207-10.
27. University of Oxford and Merck Schering-Plough. SHARP: study of heart and renal protection. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://www.clinicaltrials.gov/ct2/show/NCT00125593. Accessed September 15, 2009.
28. Svenson M, Schmidt EB, Jorgensen KA, Christensen JH. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol 2006;1:780-6.
29. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376. Available from http://dx.doi.org/10.1136/bmj.b2376.
30. Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a metaanalysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370:1829-39.
31. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48:438-45.
32. U.S. National Institutes of Health, National Heart, Lung, and Blood Institute. Detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel IV). Available from http://www.nhlbi.nih.gov/ guidelines/cholesterol/atp4/index.htm. Accessed May 31, 2010.